Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Poland / NCT07023094
Recruiting Phase 4

PENG With LFCB vs. ESP Blocks for Pediatric Hip Surgery

NCT07023094 · tracked via the Priya Life Science Poland tracker
Sponsor
Poznan University of Medical Sciences
Phase
Phase 4
Started
2025-06-16
Last updated
2025-07-11

Condition(s) studied

Hip DiseaseHip DysplasiaHip Arthropathy

Investigational drug(s) / intervention(s)

Ropivacaine 0.2% for PENG BlockRopivacaine 0.2% for LFCBRopivacaine 0.2% for L-ESPBRopivacaine 0.2% for S-ESPB

Ropivacaine 0.2% for PENG Block: U-S guided PENG (0.4 mL/kg) with 0.2% ropivacaine

Ropivacaine 0.2% for LFCB: LFCB (0.1 mL/kg) with 0.2% ropivacaine

Ropivacaine 0.2% for L-ESPB: Lumbar ESPB (0.25ml/kg) with 0.2% ropivacaine

Ropivacaine 0.2% for S-ESPB: Sacral ESPB (0.25ml/kg) with 0.2% ropivacaine

Study summary

This randomized controlled trial (RCT) compares the analgesic effectiveness of two regional anesthesia techniques-Pericapsular Nerve Group (PENG) block combined with Lateral Femoral Cutaneous Nerve Block (LFCB) versus Lumbar and Sacral Erector Spinae Plane Blocks (L-ESPB and S-ESPB)-in pediatric patients undergoing hip surgery.

Eligibility

Sex
ALL
Min age
2 Years
Max age
16 Years
Healthy volunteers
No
Inclusion Criteria: * Pediatric patients aged between 2 and 16 years. * Scheduled for elective orthopedic hip surgery, including: Osteotomies and Hip reconstruction surgeries * ASA (American Society of Anesthesiologists) physical status classification: I-III. * Written informed consent obtained from the patient's legal guardian(s). Exclusion Criteria: * Known allergy or hypersensitivity to any of the study medications * Presence of infection or inflammation at the intended injection site(s) of regional anesthesia. * Coagulopathy or bleeding disorders (including patients on anticoagulant therapy) that contraindicate nerve blocks. * Neurological disorders or peripheral neuropathies that could influence sensory or motor assessment of the lower limbs. * Cognitive impairment or behavioral disorders significantly affecting pain assessment accuracy or cooperation. * History of chronic opioid use or known substance abuse. * Severe systemic disease or condition compromising patient safety or interfering with study protocol adherence.

Primary outcome measure(s)

  • Total Opioid Consumption — 48 hours after surgery
    Total opiate consumption after surgery

Trial sites (1)

FacilityCityRegionStatus
Poznan University of Medical Sciences Poznan Poland Recruiting

More Poznan University of Medical Sciences trials in Poland

SII Levels Following iPACK Block With Adductor Canal Block in Knee Arthroplasty Recruiting
Demographic and Interpopulation Variations in Evaluation and Results of TAVI Enrolling by invitation
Lumbar Paravertebral Block vs Erector Spinae Plane Block in Elderly Patients Undergoing Lumbar Spine Surgery Starting soon
PENG Block Variants With Dexamethasone and Dexmedetomidine in Older Adults Recruiting
Will the Use of Respiratory Quotient ''RQ'' Improve Treatment Outcomes for Intensive Care Unit (ICU) Patients? Recruiting

Other trials for the same condition

SII Levels Following PENG Block in Pediatric Hip Surgery Starting soon
PENG vs L-ESPB With S-ESPB for Analgesia in Total Hip Arthroplasty Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07023094 on ClinicalTrials.gov ↗ ← All trials in Poland